Effects of L-Carnitine supplement on plasma coagulation and anticoagulation factors in hemodialysis patients
| Autor: | Hadi Tabibi, Mehdi Hedayati, Tahereh Malakoutian, Fariba Hakeshzadeh, Minoo Ahmadinejad |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Adult
Male lcsh:Internal medicine medicine.medical_specialty lcsh:Specialties of internal medicine Urology medicine.medical_treatment Critical Care and Intensive Care Medicine Thrombophilia Placebo Fibrinogen Tissue plasminogen activator Gastroenterology Double-Blind Method lcsh:RC581-951 Renal Dialysis Internal medicine Carnitine medicine Humans lcsh:RC31-1245 Blood Coagulation Aged biology business.industry C-reactive protein General Medicine Middle Aged medicine.disease Thrombosis Blood proteins Blood Coagulation Factors Surgery C-Reactive Protein Coagulation Nephrology Cardiovascular Diseases Vitamin B Complex biology.protein Kidney Failure Chronic Female Hemodialysis business Plasminogen activator medicine.drug |
| Zdroj: | Kidney Research and Clinical Practice, Vol 31, Iss 2, p A33 (2012) |
| ISSN: | 1525-6049 |
| Popis: | BackgroundHypercoagulability is an important risk factor for thrombosis and its complications in hemodialysis patients. This study was designed to investigate the effects of L-carnitine supplement on plasma coagulation and anticoagulation factors in hemodialysis patients.MethodsThirty-six hemodialysis patients were randomly assigned to either a carnitine or a placebo group. Patients in the carnitine group received 1000 mg/day oral L-carnitine for12 weeks, whereas patients in the placebo group received a corresponding placebo. At baseline and the end of week12, 5 mL blood was collected after a 12- to 14-hour fast and plasma fibrinogen concentration, activity of plasma proteinC, coagulation factors V, VII, IX, and serum concentrations of tissue plasminogen activator (tPA), plasminogen activator inhibitor type-1 (PAI-1), free carnitine, and C-reactive protein (CRP) were measured. Results: In the carnitine group, mean serum free carnitine concentration increased significantly to 150% of baseline (p < 0.001), whereas plasma fibrinogen and serum CRP had 98 mg/dL (p < 0.01) and 41% (p < 0.01) significant decreases, respectively, at the end of week 12 compared with baseline. The reductions were significant compared with the placebo group (p < 0.05).No significant differences were observed between the two groups with regard to mean changes of the activity of plasma protein C, coagulation factors V, VII, IX, and serum PAI-1 to tPA ratio.Conclusion: L-Carnitine supplement reduces serum CRP, a marker of systemic inflammation, and plasma fibrinogen, an inflammation-related coagulation factor, in hemodialysis patients. Therefore, L-carnitine may play an effective role in preventing cardiovascular diseases in these patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|